A high throughput drug screening assay to identify compounds that promote oligodendrocyte differentiation using acutely dissociated and purified oligodendrocyte precursor cells

• Published in: BMC research notes 2016-09, Vol.9 (1), p.419-419, Article 419
• Main Authors: Lariosa-Willingham, Karen D, Rosler, Elen S, Tung, Jay S, Dugas, Jason C, Collins, Tassie L, Leonoudakis, Dmitri
• Format: Article
• Language: English
• Subjects: Animals; Care and treatment; Cell differentiation; Cell Differentiation - drug effects; Clinical trials; Dendritic cells; Drug Evaluation, Preclinical - methods; Health aspects; In Vitro Techniques; Methods; Multiple sclerosis; Multiple Sclerosis - drug therapy; Oligodendroglia - cytology; Oligodendroglia - drug effects; Rats; Stem Cells - cytology; Stem Cells - drug effects; Technical Note
• ISSN: 1756-0500; 1756-0500
• DOI: 10.1186/s13104-016-2220-2

Multiple sclerosis is caused by an autoimmune response resulting in demyelination and neural degeneration. The adult central nervous system has the capacity to remyelinate axons in part through the generation of new oligodendrocytes (OLs). To identify clinical candidate compounds that may promote remyelination, we have developed a high throughput screening (HTS) assay to identify compounds that promote the differentiation of oligodendrocyte precursor cells (OPCs) into OLs. Using acutely dissociated and purified rat OPCs coupled with immunofluorescent image quantification, we have developed an OL differentiation assay. We have validated this assay with a known promoter of differentiation, thyroid hormone, and subsequently used the assay to screen the NIH clinical collection library. We have identified twenty-seven hit compounds which were validated by dose response analysis and the generation of half maximal effective concentration (EC50) values allowed for the ranking of efficacy. The assay identified novel promoters of OL differentiation which we attribute to (1) the incorporation of an OL toxicity pre-screen to allow lowering the concentrations of toxic compounds and (2) the utilization of freshly purified, non-passaged OPCs. These features set our assay apart from other OL differentiation assays used for drug discovery efforts. This acute primary OL-based differentiation assay should be of use to those interested in screening large compound libraries for the identification of drugs for the treatment of MS and other demyelinating diseases.